Skip to main content

Table 2 Univariate and multivariate analyses of disease-free survival

From: Enhancing prognosis prediction using pre-treatment nodal SUVmax and HPV status in cervical squamous cell carcinoma

Variables

Univariate analysis

Multivariate analysis

HR

95% CI

p-value

HR

95% CI

p-value

Agea

0.98

0.95–1.01

0.140

   

FIGO stage

2.02

1.36–3.00

< 0.001

   

Tumor sizea

1.43

1.14–1.08

0.002

1.37

1.06–1.77

0.015

Pelvic lymph node

1.89

0.90–3.96

0.094

   

Para-aortic lymph node

4.21

1.89–9.40

< 0.001

3.75

1.39–10.15

0.009

SCC antigena

1.01

1.00–1.01

0.122

   

pSUVmaxa

1.04

0.99–1.08

0.086

   

Nodal SUVmaxa

1.07

1.04–1.11

< 0.001

1.05

1.01–1.09

0.020

HPV negative

2.37

1.01–5.55

0.047

3.68

1.44–9.41

0.007

  1. aAge, Tumor size, SCC antigen, pSUVmax, nodal SUVmax were analyzed as continuous variables. Hazard ratio represents the increase in hazard for each variable
  2. HR hazard ratio, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, SUVmax maximum standardized uptake, pSUVmax SUVmax of primary tumor, nodal SUVmax SUVmax of the lymph node with the highest FDG uptake, HPV human papilloma virus